Welcure Drugs (524661)

Score breakdown: P/E: 3/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Let me be blunt: this is not a business I can understand from these numbers, and that alone disqualifies it in my book. Welcure Drugs sells at ₹6.99, market cap ₹55 crore, yet latest quarter sales are ₹0 crore. Zero revenue. The company shows ₹1 crore net profit—where did it come from? Not from operations. ROE is 34.77% but ROCE is 2.53%, a huge gap that tells me reported earnings are not generated by productive capital employed. Sales growth is -100%, while profit growth is supposedly 1000%; that is arithmetic from a base of nothing, not a compounding franchise. P/E of 1.08 looks tantalising, but only if the profit is real, recurring, and cash; I have no evidence. Book value is ₹0.89, so paying ₹6.99 means 7.85 times book for a shell with no revenue. The 52-week range of ₹0.23 to ₹6.99 shows the market has already gone mad for it; I don't chase such moves. Piotroski F-score 6/9 is mediocre, and the FairStock Score says insufficient data. Promoter holding is unknown, dividend is nil. This is a penny-stock spectacle, not a business. If there is a genuine turnaround, I need audited financials, a path to real sales, and honest management. Until then, I would rather miss it.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer